Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicitie

被引:44
作者
Guha, Avirup [1 ]
Armanious, Merna [2 ,3 ]
Fradley, Michael G. [2 ,3 ]
机构
[1] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA
[2] Univ S Florida, Div Cardiovasc Med, Cardiooncol Program, 2 Tampa Gen Circle, Tampa, FL 33606 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Cardiooncol Program, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; Proteasome inhibitors; CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; METASTATIC BREAST-CANCER; HISTONE DEACETYLASE INHIBITORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; PLATINUM-BASED CHEMOTHERAPY; ARTERIAL OCCLUSIVE DISEASE; DABRAFENIB PLUS TRAMETINIB; MISMATCH REPAIR-DEFICIENT;
D O I
10.1016/j.tcm.2018.06.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:29 / 39
页数:11
相关论文
共 235 条
[21]   Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic-Pharmacodynamic Evaluation of Sunitinib [J].
Bello, Carlo L. ;
Mulay, Marilyn ;
Huan, Xin ;
Patyna, Shem ;
Dinolfo, Melissa ;
Levine, Steven ;
Van Vugt, Andrew ;
Toh, Melvin ;
Baum, Charles ;
Rosen, Lee .
CLINICAL CANCER RESEARCH, 2009, 15 (22) :7045-7052
[22]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[23]   Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study [J].
Bowles, Erin J. Aiello ;
Wellman, Robert ;
Feigelson, Heather Spencer ;
Onitilo, Adedayo A. ;
Freedman, Andrew N. ;
Delate, Thomas ;
Allen, Larry A. ;
Nekhlyudov, Larissa ;
Goddard, Katrina A. B. ;
Davis, Robert L. ;
Habel, Laurel A. ;
Yood, Marianne Ulcickas ;
McCarty, Catherine ;
Magid, David J. ;
Wagner, Edward H. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (17) :1293-1305
[24]   Anti-VEGF-induced hypertension: A review of pathophysiology and treatment options [J].
Brinda B.J. ;
Viganego F. ;
Vo T. ;
Dolan D. ;
Fradley M.G. .
Current Treatment Options in Cardiovascular Medicine, 2016, 18 (5)
[25]   Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials [J].
Brown, Jennifer R. ;
Moslehi, Javid ;
O'Brien, Susan ;
Ghia, Paolo ;
Hillmen, Peter ;
Cymbalista, Florence ;
Shanafelt, Tait D. ;
Fraser, Graeme ;
Rule, Simon ;
Kipps, Thomas J. ;
Coutre, Steven ;
Dilhuydy, Marie-Sarah ;
Cramer, Paula ;
Tedeschi, Alessandra ;
Jaeger, Ulrich ;
Dreyling, Martin ;
Byrd, John C. ;
Howes, Angela ;
Todd, Michael ;
Vermeulen, Jessica ;
James, Danelle F. ;
Clow, Fong ;
Styles, Lori ;
Valentino, Rudy ;
Wildgust, Mark ;
Mahler, Michelle ;
Burger, Jan A. .
HAEMATOLOGICA, 2017, 102 (10) :1796-1805
[26]   Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study [J].
Bruemmendorf, Tim H. ;
Cortes, Jorge E. ;
Khoury, H. Jean ;
Kantarjian, Hagop M. ;
Kim, Dong-Wook ;
Schafhausen, Philippe ;
Zeremski, Mirjana ;
Shapiro, Mark ;
Leip, Eric ;
Gambacorti-Passerini, Carlo ;
Lipton, Jeffrey H. .
BLOOD, 2014, 124 (21)
[27]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[28]   Cardiac effects of chimeric antigen receptor (CAR) T-cell therapy in children. [J].
Burstein, Danielle S. ;
Maude, Shannon L. ;
Grupp, Stephan A. ;
Griffis, Heather ;
Rossano, Joseph W. ;
Lin, Kimberly Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29]   Cancer Treatment-Induced Arrhythmias Focus on Chemotherapy and Targeted Therapies [J].
Buza, Vitaly ;
Rajagopalan, Bharath ;
Curtis, Anne B. .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2017, 10 (08)
[30]   First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].
Carbone, D. P. ;
Reck, M. ;
Paz-Ares, L. ;
Creelan, B. ;
Horn, L. ;
Steins, M. ;
Felip, E. ;
van den Heuvel, M. M. ;
Ciuleanu, T. -E. ;
Badin, F. ;
Ready, N. ;
Hiltermann, T. J. N. ;
Nair, S. ;
Juergens, R. ;
Peters, S. ;
Minenza, E. ;
Wrangle, J. M. ;
Rodriguez-Abreu, D. ;
Borghaei, H. ;
Blumenschein, G. R. ;
Villaruz, L. C. ;
Havel, L. ;
Krejci, J. ;
Corral Jaime, J. ;
Chang, H. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Chen, A. C. ;
Socinski, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426